Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod with Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05445609Phase 2Suspended
- Sponsor
- Emory University
- Start
- Jun 2023
- Primary completion
- Jun 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vidutolimod in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Emory University. Started Jun 2023; status: suspended.
02
Drugs
vidutolimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05445609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445609.